BSRI

The International Myeloma Foundation and Black Swan Research Initiative® Announce the Release of New iStopMM Cohort Study: A Multivariable Prediction Model for Bone Marrow Sampling on Individuals with MGUS

Retrieved on: 
Thursday, April 11, 2024
Immunoglobulin G, International Myeloma Foundation, University, Bone marrow, Mayo Clinic, Randomized controlled trial, Overfitting, Multiple myeloma, Annals of Internal Medicine, MGUS, Probability, Risk, Monoclonal gammopathy, Immunoglobulin M, Research, Calibration, Immunoglobulin A, IQR, European Research Council, Clinical, IMF, SMM, B cell, Black swan, Diagnosis, Clutch (eggs), Internal medicine, Smouldering, Lymphoproliferative disorders, BSRI, Ageing, Medical device

IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.

Key Points: 
  • IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.
  • Groups 2 and 3 were evaluated at the study clinic for initial assessment and follow-up, including bone marrow sampling,” according to the study.
  • However, [this] model requires validation in other populations.”
    To know the full details of the iStopMM cohort study , view it online.
  • This research was funded by the International Myeloma Foundation and the European Research Council.

Lifelong Philanthropist and 17-year Myeloma Survivor John O’Dwyer Elected to the International Myeloma Foundation’s Board of Directors

Retrieved on: 
Thursday, March 14, 2024
Multiple myeloma, Pregnancy, Organization, Bone marrow, Development, Strategic planning, Disease, Patient, Celanese, Research, Cancer, University, IMF, Volunteering, Quality of life, United Way, Marketing, Woman, Black swan, International Myeloma Foundation, Thalidomide, MRD, International business, Loyola University Chicago, BSRI, Loyola University, Kellogg School of Management

STUDIO CITY, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is thrilled to welcome lifelong philanthropist and 17-year myeloma survivor John O’Dwyer to the IMF Board.

Key Points: 
  • STUDIO CITY, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is thrilled to welcome lifelong philanthropist and 17-year myeloma survivor John O’Dwyer to the IMF Board.
  • Prior to his recent election, John served on the IMF Board from 2010-2016 and made many significant contributions to advance the mission and goals of the IMF.
  • A cure is possible, but it is not free!”
    “I am thrilled to have John back on the IMF Board.
  • “I am very excited to welcome board member John O’Dwyer back to the IMF Board.

International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at the 2023 ASH Annual Meeting

Retrieved on: 
Friday, January 12, 2024
Projection screen, MGUS, Risk, Research, Body mass index, Multiple myeloma, Smoking, IMF, Thrombosis, BSRI, SMM, Sense, Conference, Abstract, ASH, Treatment, Abstract (summary), Cosmetics

( Abstract #3397: Risk Factors of Smoldering Multiple Myeloma: Results from the Screened iStopMM Study )

Key Points: 
  • ( Abstract #3397: Risk Factors of Smoldering Multiple Myeloma: Results from the Screened iStopMM Study )
    A Media Snippet accompanying this announcement is available by clicking on this link.
  • In a recent Ask Dr. Durie video , IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M.
  • Durie discusses the iStopMM Project’s purpose in doing the large-scale screening study and the advantages that come with early screening.
  • You may also access the complete list of 2023 ASH Abstract Achievement Awardees on the ASH website.

World-Renowned Scientist, S. Vincent Rajkumar, MD, Appointed as Chairman-Elect of the Board of Directors of the International Myeloma Foundation (IMF)

Retrieved on: 
Thursday, July 20, 2023
AMN, Mayo Clinic, IMF, Bone marrow, Multiple myeloma, Thalidomide, Jan, Research, Harvard Medical School, Ask, Black swan, International Myeloma Foundation, BSRI, Patient, Durie, Clinical professor, Editor-in-chief, FDA, European Journal, Disease, Management, Medical device, MD, Leukemia, Medicine

LOS ANGELES, July 20, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that world-renowned myeloma clinician and researcher S. Vincent Rajkumar, MD, has been appointed Chairman-Elect of the Board of the foundation.

Key Points: 
  • LOS ANGELES, July 20, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that world-renowned myeloma clinician and researcher S. Vincent Rajkumar, MD, has been appointed Chairman-Elect of the Board of the foundation.
  • Dr. Durie will remain a member of the Board of Directors and will hold the new position of Chairman Emeritus.
  • Dr. Durie is very pleased that Dr. Rajkumar has agreed to take on the responsibility as Chairman of the IMF Board of Directors.
  • “Dr.

International Myeloma Foundation (IMF) Returns to In-Person Patient and Family Seminars in 2023, Announces Boca Raton Event

Retrieved on: 
Thursday, February 2, 2023
BSRI, Health, Education, Hematology, Society, Safety, Patient, Trial of the century, COVID-19, International Myeloma Foundation, Cancer, Multiple myeloma, Family, Heel, IMF, MSN, FAAN, Environment, 2021 Essex County Council election, BOCA, University, Doctor of Philosophy, Pharmaceutical industry, Medical device, Medicine, MD

BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that this year’s first Patient and Family Seminar is taking place in-person and virtually on March 17–18, 2023, in Boca Raton, Florida.

Key Points: 
  • BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that this year’s first Patient and Family Seminar is taking place in-person and virtually on March 17–18, 2023, in Boca Raton, Florida.
  • IMF Patient and Family Seminars gather doctors, patients, and families alike to share stories and connect with those on similar journeys in the myeloma community.
  • The Boca Raton Patient and Family Seminar will include presentations from internationally esteemed myeloma researchers from all over the world.
  • Leading up to the event, the IMF will announce additional expert speakers for the upcoming Boca Raton Patient and Family Seminar.

The International Myeloma Foundation (IMF) Highlights #kNOwMyeloma Campaign for Blood Cancer Awareness Month 2022

Retrieved on: 
Wednesday, August 31, 2022
Neoplasm, African Americans, Immunotherapy, Spine, Bristol Myers Squibb, Research, India Infoline, IMF, CAR, Skull, Awareness, Rib cage, BSRI, Disease, Multiple myeloma, International Myeloma Foundation, Black swan, Board, Hope, Blood, Congress, LinkedIn, Diagnosis, Quality of life, Education, Goal, Foundation, Lymphatic system, Pelvis, Antibody, Instagram, Plasma, Social media, Twitter, Bone loss, Adult, Janssen Pharmaceuticals, Johnson & Johnson, Risk, Bone marrow, Patient, Birth control, Public relations, Medical imaging, Pharmaceutical industry, Facebook

This year, the International Myeloma Foundation (IMF) is bringing multiple myelomathe second most common type of blood cancerto the forefront through its #kNOwMyeloma campaign.

Key Points: 
  • This year, the International Myeloma Foundation (IMF) is bringing multiple myelomathe second most common type of blood cancerto the forefront through its #kNOwMyeloma campaign.
  • This Blood Cancer Awareness Month, the International Myeloma Foundation asks one simple question: Do you #kNOwMyeloma?
  • In 2010, the U.S. Congress designated September as Blood Cancer Awareness Month to create awareness, increase fundraising, and support patients affected by all types of blood cancers.
  • Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest global foundation focusing specifically on multiple myeloma.

The International Myeloma Foundation (IMF) Honors 2022 Research Achievement Awardees, Dr. Hervé Avet-Loiseau and Dr. Bruno Paiva

Retrieved on: 
Wednesday, June 8, 2022
Doctor of Philosophy, R, Multiple myeloma, International Myeloma Foundation, Immunoglobulin M, COVID-19, SNP, Food and Drug Administration, Black swan, European Medicines Agency, MGUS, IMF, In situ hybridization, Fluorescence, Food, Laboratory, Mayo, IFM, MRD, Acute myeloid leukemia, Quality of life, MD, Free University of Brussels (1834–1969), Foundation, Genomics, Biology, EMA, Monoclonality, Doctor of Pharmacy, University, EMMA, Kyle, Patient, India Infoline, Flow cytometry, Teaching hospital, Fish, Risk, Education, WM, MM, AL, NGS, Research, Society, SMM, American Society of Clinical Oncology, Lymphatic system, Disease, ASCO, Chinese, University Hospital Center Dr Dragiša Mišović, BSRI, FDA, Research and development, Gene expression profiling, Board, Pharmaceutical industry, Management, Medicine

The Kyle and Durie Achievement Awards are presented each year to outstanding and deserving individuals who have made significant contributions in the field of myeloma research.

Key Points: 
  • The Kyle and Durie Achievement Awards are presented each year to outstanding and deserving individuals who have made significant contributions in the field of myeloma research.
  • The Robert A. Kyle Lifetime Achievement Award honors individuals whose work have resulted in significant advances in research, treatment, and care of myeloma patients.
  • Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest global foundation focusing specifically on multiple myeloma.
  • In 2012, the IMF launched the Black Swan Research Initiative, a groundbreaking research project aimed at curing myeloma.